CS
KYMR icon

Credit Suisse’s Kymera Therapeutics KYMR Stock Holding History

Credit Suisse’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$9.15M Buy
227,586
+63,434
+39% +$2.27M 0.01% 954
2023
Q4 		$4.18M Buy
164,152
+126,822
+340% +$2.27M ﹤0.01% 1434
2023
Q3 		$519K Sell
37,330
-10,149
-21% -$204K ﹤0.01% 2670
2023
Q2 		$1.09M Buy
47,479
+12,148
+34% +$348K ﹤0.01% 2331
2023
Q1 		$1.05M Buy
35,331
+3,066
+10% +$98.9K ﹤0.01% 2300
2022
Q4 		$805K Buy
32,265
+657
+2% +$17.5K ﹤0.01% 2487
2022
Q3 		$689K Buy
31,608
+8,364
+36% +$220K ﹤0.01% 2589
2022
Q2 		$457K Sell
23,244
-61
-0.3% -$1.43K ﹤0.01% 2899
2022
Q1 		$987K Buy
23,305
+3,735
+19% +$158K ﹤0.01% 2560
2021
Q4 		$1.24M Buy
19,570
+2,973
+18% +$173K ﹤0.01% 3150
2021
Q3 		$975K Buy
16,597
+9,906
+148% +$574K ﹤0.01% 3364
2021
Q2 		$324K Sell
6,691
-3,093
-32% -$134K ﹤0.01% 4082
2021
Q1 		$380K Sell
9,784
-1,133
-10% -$68.2K ﹤0.01% 3910
2020
Q4 		$677K Buy
+10,917
New +$533K ﹤0.01% 3621

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Credit Suisse's KYMR Position: Q1 2024 in Review

Credit Suisse increased its Kymera Therapeutics (KYMR) stake by 39% in Q1 2024, buying an estimated $2.27M and bringing the position to 227,586 shares worth $9.15M. The position accounts for 0.01% of the portfolio, ranked #954.

Credit Suisse first reported a position in KYMR in Q4 2020 and has held it in 14 quarters since. 164 funds tracked by Wall St. Rank hold KYMR as of Q1 2024.

  • Credit Suisse held 227,586 shares of Kymera Therapeutics worth $9.15M as of Q1 2024.
  • Credit Suisse bought 63,434 Kymera Therapeutics shares in Q1 2024, an estimated $2.27M.
  • Kymera Therapeutics made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #954 holding.
  • Credit Suisse first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • 164 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.